2
13
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TP1651L |
Proinsulin C-peptide human acetate
醋酸胰岛素原C-肽(55-89),人,Proinsulin C-peptide human acetate (33017-11-7 Free base) |
Others | Others |
Proinsulin C-peptide human acetate (Proinsulin C-peptide human acetate (33017-11-7 Free base)) 是一种由31个氨基酸残基组成的多肽,它连接胰岛素原的 A 链和 B 链以确保正确折叠,具有生物活性并调节细胞功能。 | |||
TP1651 |
Proinsulin C-peptide (human)
Proinsulin C-peptide human |
||
Proinsulin C-peptide (human) is a 31-amino acid peptide that connects the Proinsulin a and B chains, ensuring its proper folding, biological activity, and regulation of cellular functions. |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01491 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HBV,Hepatitis B virus |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01501 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein, Human, MHC (His & Avi)
MHC,Hepatitis B virus,HBV |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01505 |
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein, Human, MHC (His & Avi), Biotinylated
E7,MHC,HPV16 |
Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. | |||
TMPK-01492 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi)
Hepatitis B virus,HBV,MHC |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01504 |
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Tetramer Protein, Human, MHC (His & Avi)
MHC,HPV16,E7 |
Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. | |||
TMPK-01506 |
HLA-A*02:01&B2M&HPV16 E7 (YMLDLQPET) Monomer Protein, Human, MHC (His & Avi)
HPV16,E7,MHC |
Human | HEK293 Cells |
HPV16 E7 protein, one of the primary target proteins in molecular targeted therapy for HPV-induced cervical cancer. The affitoxin, ZHPV16E7 affitoxin384 was generated by fusing the modified Pseudomonas Exotoxin A (PE38KDEL) to the HPV16 E7-specific affibody. | |||
TMPK-01534 |
Chimeric HLA-A*02:01 (mα3) &B2M&LMP2 (CLGGLLTMV) Monomer Protein, Human&Mouse, MHC (His & Avi)
RING12,PSMB9,Proteasome chain 7,RMF,LMP-2,LMP2,MH |
Human & Mouse | HEK293 Cells |
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... | |||
TMPK-01523 |
Chimeric HLA-A*02:01 (mα3) &B2M&WT-1 (RMFPNAPYL) Monomer Protein, Human&Mouse, MHC (His & Avi)
WAGR,WT33,AWT1,GUD,RMF,WT1,WIT-2,MHC,NPHS4GUD |
Human & Mouse | HEK293 Cells |
The WT1 protein plays a role in cell growth, the process by which cells mature to perform specific functions (differentiation), and the self-destruction of cells (apoptosis). WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1. | |||
TMPK-01535 |
Chimeric HLA-A*02:01 (mα3) &B2M&LMP2 (CLGGLLTMV) Tetramer Protein, Human&Mouse, MHC (His & Avi)
Macropain chain 7,LMP2,Proteasome c |
Human & Mouse | HEK293 Cells |
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... | |||
TMPK-01522 |
Chimeric HLA-A*02:01 (mα3) &B2M&WT-1 (RMFPNAPYL) Tetramer Protein, Human&Mouse, MHC (His & Avi)
RMF,WT33,WIT-2,MHC,WAGR,AWT1,GUD,WT1,NPHS4GUD |
Human & Mouse | HEK293 Cells |
The WT1 protein plays a role in cell growth, the process by which cells mature to perform specific functions (differentiation), and the self-destruction of cells (apoptosis). WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1. |